Surgical Specialties Corporation, Inc.
MarketLine (a Datamonitor Company)
17 Feb 2014
Available for Immediate Download
Angiotech Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360° view of the company. Features: - Detailed information on Angiotech Pharmaceuticals, Inc. required for business and competitor intelligence needs - A study of the major internal and external factors affecting Angiotech Pharmaceuticals, Inc. in the form of a SWOT analysis - An in-depth view of the business model of Angiotech Pharmaceuticals, Inc. including a breakdown and examination of key business segments - Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Angiotech Pharmaceuticals, Inc. - Intelligence on Angiotech Pharmaceuticals, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Angiotech Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Angiotech Pharmaceuticals* (Angiotech or ‘the company’) is a medical devices company engaged in the development, manufacturing and marketing of medical device products and technologies, primarily within the areas of interventional oncology, wound closure and ophthalmology. The company operates in the Europe, Asia-Pacific, Latin America and Canada. It is headquartered in Vancouver, Canada, and employed 1,290 people as of December 31, 2011. The company recorded revenues of $233.2 million during the financial year ended December 2011 (FY2011), a decrease of 5.3% over FY2010. The operating loss of the company was $49.1 million in FY2011, as compared to an operating loss of $20.1 million in FY2010. The net profit $319.1 million in FY2011, as compared to a net loss of $66.8 million in FY2010. *The company has filed under the US Bankruptcy Code to effectuate the Companies' Creditors Arrangement Act (CCAA) Proceedings in the US as set forth in the CCAA Plan. Reasons to Purchase: - Gain understanding of Angiotech Pharmaceuticals, Inc. and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Angiotech Pharmaceuticals, Inc. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Angiotech Pharmaceuticals, Inc.’s business structure, strategy and prospects